Continuing Education Activity

Ifosfamide, an alkylating agent and a cyclophosphamide analog, is used as a single agent or in combination with other drugs to treat various types of cancer. Ifosfamide is a cytotoxic, antineoplastic medication used to manage and treat diverse cancers, including lymphoma, sarcoma, and lung cancer. This activity outlines the indications, administration procedures, and contraindications for ifosfamide, highlighting its significance as a valuable agent in treating various cancers. This activity also reviews the mechanism of action, adverse event profile, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions of ifosfamide. This information is pertinent for the interprofessional healthcare team involved in the comprehensive management of malignancies and related conditions in patients.

Objectives:

• Identify the appropriate indications for ifosfamide, recognizing its role as a cytotoxic, antineoplastic agent to treat various malignancies, including lymphoma, sarcoma, and lung cancer.
• Implement safe and effective administration procedures for ifosfamide, considering dosing, infusion rates, and concurrent medications.
• Assess patients for potential adverse events, particularly focusing on hemorrhagic cystitis, neurotoxicity, and myelosuppression, and initiate appropriate management strategies.
• Collaborate among interprofessional healthcare teams, including pharmacists, nurses, and oncologists, to integrate ifosfamide into targeted therapeutic regimens, emphasizing a patient-centered approach for enhanced care outcomes.

Indications

Ifosfamide, an alkylating agent and a cyclophosphamide analog, is used as a single agent or in combination with other drugs to treat various types of cancer.[1] Ifosfamide is a cytotoxic, antineoplastic medication used to manage and treat diverse cancers, including lymphoma, sarcoma, and lung cancer.

FDA-Approved Indication

Germline tumor of the testis: The regimen approved by the U.S. Food and Drug Administration (FDA) involves administering ifosfamide and mesna at a 1.2 g/m²/d dose for 5 days, with repetition every 3 weeks or upon count recovery. The combination of ifosfamide with other chemotherapeutic drugs, particularly cisplatin, paclitaxel, or etoposide, has resulted in complete remission in approximately 21% to 26% of the treated population. Aggressive hydration (at least 2 L orally or intravenously (IV)) is necessary during administration.[2][3]

Off-Label Uses

Soft tissue sarcomas: Studies have shown that combination therapy with ifosfamide and mesna demonstrates objective response rates of around 40% when used as induction therapy.[4]

Ewing sarcoma: According to the American Society of Clinical Oncology (ASCO) guidelines for recurrent or refractory Ewing sarcoma, high-dose ifosfamide proves to be more effective in extending survival compared to the topotecan and cyclophosphamide regimen.[5][6]

Cervical cancer—recurrent or metastatic: Ifosfamide is administered alongside mesna at 1500 g/m²/d every 3 weeks. The response rate ranges from 18% to 45% when combined with paclitaxel and cisplatin.[7]

Bladder carcinoma: Bladder carcinoma is typically treated with ifosfamide in cases of advanced bladder cancer.[8]

Non-Hodgkin lymphoma: Ifosfamide is salvage therapy in Burkitt lymphoma and diffuses large B-cell lymphoma.

Hodgkin lymphoma: In relapsed or refractory cases, ifosfamide is administered as part of the RICE regimen (rituximab, ifosfamide, carboplatin, and etoposide) along with mesna.[9]

Small-cell and non-small-cell lung cancer: Studies have shown that ifosfamide provides more benefits than standard regimens when used as maintenance or consolidation therapy.[10]

Osteosarcoma: High-dose ifosfamide proves to be an effective, standalone treatment for patients with refractory or recurrent osteosarcoma.[11][12]

Thymic cancer: Ifosfamide is used in advanced stages of thymic carcinoma.[13]

Ovarian cancer: Ifosfamide is used in platinum-resistant advanced stages, with ongoing trials exploring its efficacy. Combination therapy involving ifosfamide has demonstrated response rates surpassing 40%.[14]

Mechanism of Action

The mechanism of action of ifosfamide—classified as an oxazaphosphorine alkylating agent—involves the following steps:

• Ifosfamide is an inactive prodrug that exists in its parent form and undergoes hepatic metabolism facilitated by CYP450 enzymes, generating active metabolites. These metabolites, including phosphoramide mustard derivatives and acrolein, bind to DNA and inhibit DNA synthesis.[15]

• These metabolites operate through 2 distinct mechanisms. First, they induce cell damage by forming interstrand or intrastrand crosslinks, leading to apoptosis of the damaged cell. Second, the active metabolites upregulate reactive oxygen species (ROS), resulting in irreparable DNA damage and the cessation of protein formation.

• Compared to other alkylating compounds, cyclophosphamide and ifosfamide have more antitumor activity as their derivatives. Mainly, phosphoramide mustard derivatives and acrolein are cytotoxic rather than cytostatic. Renal filtration predominantly facilitates elimination, necessitating dosage adjustments based on renal function.[16]

Pharmacokinetics

Absorption: Although the oral formulation of ifosfamide demonstrates good bioavailability, its first-pass metabolism produces a metabolite associated with excessive neurotoxicity. Consequently, ifosfamide is administered IV to mitigate this potential issue.[17]

Distribution: Ifosfamide exhibits a volume of distribution (Vd) approximating total body water, indicating minimal tissue binding. Median Vd values stand at 0.64 L/kg (on day 1) and 0.72 L/kg (on day 5). Although plasma protein binding of ifosfamide is minimal, its active metabolites extensively bind to red blood cells.

Metabolism: Ifosfamide undergoes extensive metabolism, producing toxic metabolites, particularly acrolein and chloro-acetaldehyde.[18]

Elimination: Ifosfamide has a half-life of 15 hours when administered at high doses (3800 to 5000 mg/m²) and 7 hours at low doses (1800 to 2400 mg/m²). The primary route of excretion is through urine.

Administration

Adult Dosage

The primary method of administering ifosfamide is through the IV route.[2]

For germ-cell testicular cancer, the prescribed dosing regimen entails IV administration of 1.2 g/m²/d for the initial 5 days within a 21-day cycle. IV infusion is typically conducted over 30 minutes, accompanied by concurrent IV hydration and mesna administration to mitigate the risk of bladder toxicity. As ifosfamide is emetogenic, antiemetics are routinely prescribed to prevent chemotherapy-induced nausea and vomiting. Notably, the literature reports instances of aprepitant precipitating ifosfamide-induced encephalopathy (IIE).[19][20]

Although ifosfamide was discovered by researchers over 2 decades ago, its use was initially constrained by dose limitations due to the development of hemorrhagic cystitis. With the introduction of the thiol neuroprotective compound mesna, ifosfamide became more widely used in treating various malignancies. Consequently, the administration is almost always accompanied by mesna. Mesna undergoes conversion to dimesna in the plasma, gets filtered at the kidneys, and is then transformed back into mesna.

Within the urothelium, mesna forms a nontoxic compound when combined with active metabolites, such as acrolein (urotoxic), which is subsequently eliminated in the urine. Mesna can be administered either orally or by IV route. The half-life of mesna is approximately 0.4 hours, and it is entirely excreted within 4 hours when administered IV and within 8 hours when administered orally.[2]

Specific Patient Populations

Hepatic impairment: Given that ifosfamide undergoes substantial hepatic metabolism, yielding both therapeutic and potentially harmful metabolites, caution is advised when prescribing this medication to individuals with hepatic impairment. Ifosfamide has been associated with the risk of causing acute liver injury, including cholestatic hepatitis.[21]

Renal impairment: Close monitoring is essential for patients with renal impairment, and consideration should be given to dose reduction, as detailed in the Monitoring section.

Pregnancy considerations: Ifosfamide can cause neonatal anemia and growth retardation. According to ACOG, ifosfamide use increases the risk of ovarian dysfunction.[22]

Breastfeeding considerations: Breastfeeding is not advisable during maternal antineoplastic drug therapy, especially with alkylating agents such as ifosfamide. Guidelines discourage breastfeeding during treatment and for 1 week after the final dose of ifosfamide or mesna due to potential effects on breast milk composition and the microbiome. Pregnant women undergoing chemotherapy may face challenges in nursing their infants.[23]

Pediatric patients: Ifosfamide's safety and efficacy have not been established in the pediatric age group, and its use is considered off-label in this population.

Older patients: Caution should be exercised in selecting doses for older patients, considering the higher likelihood of decreased hepatic, renal, or cardiac function, along with concurrent illnesses or drug therapy. Careful dose selection and renal function monitoring are advisable in this population.

Adverse Effects

The adverse effects of ifosfamide are mainly dose-related and can be categorized based on the system affected.[24] These include gastrointestinal, dermatological, central nervous system, hematological, renal, endocrinal, hepatic, and cardiac.[25][26]

Gastrointestinal: Common adverse effects include nausea and vomiting (experienced by over 50% of patients), abdominal cramps, and anorexia. During this therapy, patients are typically encouraged to maintain hydration and drink ample water.[25] Antiemetics are generally administered concomitantly with the drug to manage the adverse effects. 

Dermatological: Alopecia is a prevalent adverse effect observed with ifosfamide, affecting approximately 90% of individuals undergoing this treatment.

Central nervous system: Encephalopathy is a reported adverse effect, occurring in approximately 15% of cases with ifosfamide treatment.

Renal: Hematuria is a common adverse effect observed in approximately 90% of cases when ifosfamide is used alone.

Endocrinal and metabolic: Metabolic acidosis occurs in approximately 30% of cases with ifosfamide use.

Cardiac: Arrhythmia is an infrequent adverse effect, reported in less than 10% of cases with ifosfamide use.

Hepatic: The severity of the liver injury associated with ifosfamide spans from mild elevations in liver enzymes to severe outcomes such as massive, fatal hepatic necrosis.[21]

Hematological: Common hematological adverse effects include leukopenia, anemia, and thrombocytopenia, with prevalence ranging from 30% to 50%. In addition, there is a risk of tumor lysis syndrome.[27]

Drug-Drug Interactions

CYP3A4 inducers: Ifosfamide, undergoing metabolism by CYP3A4, may experience enhanced metabolism and potentially intensified therapeutic effects when coadministered with CYP3A4 inducers such as phenobarbital, rifampin, carbamazepine, phenytoin, and St John's wort.[28] This interaction may also elevate the risk of generating toxic metabolites, necessitating close monitoring and potential adjustments to the dose.

CYP3A4 inhibitors: Coadministration of ifosfamide with CYP3A4 inhibitors such as itraconazole, sorafenib, grapefruit juice ketoconazole, and aprepitant or fosaprepitant can reduce its metabolism, potentially decreasing therapeutic effectiveness.[29] Healthcare providers should exercise caution and consider alternative treatments or dosage adjustments in such cases to maintain efficacy.

Live vaccines: Simultaneous administration of ifosfamide with live vaccines is not recommended.

Contraindications

Contraindications for ifosfamide use are limited. The absolute contraindications are known hypersensitivity to the drug or its components and urinary tract outflow obstruction. Relative contraindications include myelosuppression and severe renal or hepatic impairment.

Key facts to keep in mind with the administration of ifosfamide are as follows: 

• Administration of ifosfamide or its excipients can result in anaphylaxis in individuals with known hypersensitivity.[17]
• Urinary outflow obstruction increases the risk of developing cystitis due to the accumulation of toxic compounds.[30]
• Ifosfamide is avoided in severe thrombocytopenia and leukopenia cases due to its well-documented hematological toxicity.
• Ifosfamide is contraindicated in cases of severe renal and hepatic impairment, as it is metabolized by the liver and eliminated by the kidneys.[31]
• Ifosfamide use has been associated with an increased risk of developing secondary malignancies, including leukemia, lymphoma, sarcomas, and thyroid cancer.

Box Warning

The FDA has issued box warnings for urotoxicity, neurotoxicity, and myelosuppression associated with the use of ifosfamide.[32]

Monitoring

To understand the drug's therapeutic index, one needs to know the pharmacokinetics and pharmacodynamics of the drug. Regarding pharmacokinetics, the Vd of the drug is almost equal to the total body water when administered in the IV form. The value of Vd is subject to variations based on factors such as weight and age, including considerations for older and pediatric populations.[17] Vd increases with age and in individuals with obesity.[2] After a single administration, the drug exhibits a half-life of 4 to 7 hours, and its total clearance is 3.6 L/h. Usually, fractionation of the drug results in faster elimination rates.

The standard dosage is typically 1.2 g/m²/d, administered slowly over 30 minutes for 5 consecutive days.[2] Before administering each dose, it is necessary to conduct a comprehensive assessment, including a complete blood cell count with differential, evaluation of renal and liver function, assessment of urine output, and urinalysis. Dosing is repeated every 3 weeks or after hematological recovery. Drug levels can be measured in urine by gas chromatography-mass spectrometry.[33] Therapeutic drug monitoring takes place after assessing the pharmacokinetics of the first course of the drug, and subsequent dosage adjustments are made due to the considerable variability in ifosfamide's pharmacokinetics.

Dosage adjustments are necessary for renal impairment as the drug undergoes renal elimination.[34] For creatinine clearance (CrCl) in the range of 46 to 60 mL/min, dose reduction is 80% of the standard dose. If CrCl is between 31 and 45 mL/min, 75% of the dose should be administered, and for CrCl below 30 mL/min, the dosage should be reduced to 70% of the regular amount.[35]

The dosage should be adapted based on the toxicity profile. Instances of severe leukopenia or thrombocytopenia necessitate a reduction in dosage. In cases of more severe toxicity, such as encephalopathy, discontinuation of therapy is usually warranted.

Toxicity

Most of the ifosfamide toxicity is due to its active metabolites. Acrolein, in particular, significantly contributes to major renal and bladder-related toxicity. As the kidneys filter these metabolites, they generate ROS and nitrogen compounds that damage the renal and urothelial cells. The etiology of neurotoxicity is similar to renal toxicity but is not fully understood. As with other antineoplastic drugs, ifosfamide is toxic to bone marrow. Additional toxicities associated with ifosfamide are mentioned below.

Hemorrhagic Cystitis

Before the availability of mesna, the main adverse effect was hemorrhagic cystitis. This is due to hepatic metabolism producing acrolein, which is excreted by the kidneys and accumulates in the bladder.[30] The apoptotic properties of acrolein, along with its production of multiple ROS and nitric oxide, lead to the release of numerous cytokines, causing ulceration of the bladder epithelium and resulting in hemorrhagic cystitis. Mesna, developed in 1983, was specifically designed to address this adverse effect associated with ifosfamide.

As described earlier, mesna combines with the urotoxic metabolites at the urothelial level, forming a nontoxic product for excretion in the urine. Notably, it is crucial to aim to prevent the development of cystitis rather than address it after onset. The current treatment options are continuous bladder irrigation, intravesicular infusion of ammonium potassium sulfate and formalin, and, in some instances, cystectomy.[30] Mesna administration is recommended before, during, and after ifosfamide treatment, accompanied by aggressive hydration of at least 2 L—oral or intravenous to prevent urotoxicity.

Neurotoxicity

Central nervous system toxicity manifests as encephalopathy with varying severity, presenting symptoms such as confusion, hallucinations, drowsiness, and, in severe cases, coma. This occurs in approximately 30% of cases, with symptoms more prominent during the administration of high doses, particularly through oral administration.[36] Usually, the symptoms present within 2 to 96 hours after drug administration and are reversible within 48 to 72 hours following discontinuation of the drug.[17] Risk factors associated with the development of neurotoxicity include oral administration, previous chemotherapy with cisplatin, impaired renal and hepatic function, low albumin, and brain metastasis.

Methylene blue can be used for the treatment and prophylaxis of ifosfamide-induced encephalopathy (IIE) due to its ability to inhibit the formation of neurotoxic metabolites associated with this condition.[37] Administration of methylene blue has been shown to reverse symptoms within 24 hours. The recommended dosage is 50 mg orally in a 5% glucose solution every 4 hours until recovery.[17] As a prophylactic measure, methylene blue can mitigate the severity of symptoms compared to previous cycles, allowing the resumption of ifosfamide therapy. The recommended prophylactic dose is 50 mg IV every 6 to 8 hours during ifosfamide administration. Prescribers should exercise caution regarding the potential for serotonin syndrome with methylene blue, especially when the patient is concurrently prescribed serotoninergic medications.[38]

Hematologic Toxicity

Myelosuppression is a dose-limiting toxicity, with blood counts reaching their nadir approximately 8 to 13 days into the treatment cycle. Recovery typically occurs around day 17 of the treatment cycle, allowing for the commencement of the next cycle approximately 3 weeks after the first treatment. The incidence of myelosuppression is lower when fractionated doses are used instead of higher doses.[39] At a dosage of 1.2 g/m²/d for 5 days, around 30% of cases experience a white cell count below 3×10⁹/L and a platelet count below 20,000/μL.[39] According to the joint American Society of Clinical Oncology (ASCO)/Infectious Diseases Society of America (IDSA) guideline, patients receiving ifosfamide at doses >9 g/m² are at a higher risk for febrile neutropenia.[40]

Nephrotoxicity

Nephrotoxicity is most commonly observed in children, particularly when ifosfamide is coadministered with cisplatin. This combination can lead to Fanconi syndrome, impairing proximal tubule function and causing irreversible damage. Fanconi syndrome presents with metabolic acidosis, polyuria, and renal phosphate wasting, occurring in approximately 5% of cases. Furthermore, providing vitamin D and phosphate supplementation is crucial to address these effects in the affected pediatric population.[41] According to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines, ifosfamide-induced nephrotoxicity is attributed to its mechanism of inhibiting DNA synthesis. This inhibition leads to DNA strand–breaking effects, culminating in acute tubular injury and necrosis.[42]

Miscellaneous Toxicities

Other toxicities, including arrhythmias, heart failure, and pulmonary toxicity in the form of pneumonitis, have been reported.[43]

Ureter and Bladder Malignancies

Multifocal urothelial carcinoma has been reported in patients treated with ifosfamide several years ago.[15]

Enhancing Healthcare Team Outcomes

The administration and monitoring of chemotherapy drugs, including ifosfamide, are crucial in nursing and pharmacy. Effective collaboration among all healthcare providers within an interprofessional team is essential to ensure optimal care and minimize the adverse effects of chemotherapeutic agents. Nursing staff are crucial in closely monitoring patients during and after drug administration, identifying adverse reactions, and promptly reporting them. With specialized training in chemotherapy administration, oncology nurses contribute significantly to ensuring patient safety and well-being. Pharmacists help formulate and monitor dosing to prevent potential toxicity. The collaboration between nurses and pharmacists is essential for providing patient counseling about the drug, including expectations following administration and throughout the treatment cycles. 

A study conducted to integrate nurse practitioners, physician assistants, and pharmacists as limited oncology practice providers (LOPPs) within an academic medical center aimed to evaluate the implementation of a privileging process for these healthcare professionals. The results indicated a positive influence of LOPPs on oncology practice, with oncologists and advanced practice providers reporting beneficial outcomes.[44] An interprofessional healthcare team is crucial for optimizing ifosfamide therapy outcomes through effective communication and coordination.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst. 1988 Jun 15;80(8):556-66. [PubMed: 3286879]

2.

Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991 Sep;42(3):428-67. [PubMed: 1720382]

3.

Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, Bosl GJ, Motzer RJ. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005 Sep 20;23(27):6549-55. [PubMed: 16170162]

4.

Noujaim J, Constantinidou A, Messiou C, Thway K, Miah A, Benson C, Judson I, Jones RL. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. Am J Clin Oncol. 2018 Feb;41(2):147-151. [PubMed: 26523439]

5.

Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin RS. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist. 2017 Oct;22(10):1271-1277. [PMC free article: PMC5634776] [PubMed: 28710342]

6.

Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J. Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023 Oct 20;41(30):4794-4820. [PubMed: 37579248]

7.

Scandurra G, Scibilia G, Banna GL, D'Agate G, Lipari H, Gieri S, Scollo P. Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma. J Gynecol Oncol. 2015 Apr;26(2):118-24. [PMC free article: PMC4397227] [PubMed: 25686397]

8.

Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013 Feb 01;119(3):540-7. [PMC free article: PMC3828072] [PubMed: 22914978]

9.

Fukunaga A, Hyuga M, Iwasaki M, Nakae Y, Kishimoto W, Maesako Y, Arima N. Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. J Clin Exp Hematop. 2016;56(1):50-4. [PMC free article: PMC6144278] [PubMed: 27334858]

10.

Zhou Y, Xu Y, Zhao J, Zhong W, Wang M. [Combined Chemotherapy with Vinorelbine and Ifosfamide as Third-line Treatment and Beyond of Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2015 Jun;18(6):351-7. [PMC free article: PMC5999901] [PubMed: 26104891]

11.

Basaran M, Bavbek ES, Saglam S, Eralp L, Sakar B, Atalar AC, Bilgic B, Ozger H, Onat H. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. Oncology. 2007;72(3-4):255-60. [PubMed: 18185020]

12.

Palmerini E, Setola E, Grignani G, D'Ambrosio L, Comandone A, Righi A, Longhi A, Cesari M, Paioli A, Hakim R, Pierini M, Marchesi E, Vanel D, Pignochino Y, Donati DM, Picci P, Ferrari S. High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series. Cells. 2020 Oct 31;9(11) [PMC free article: PMC7692098] [PubMed: 33142760]

13.

Grassin F, Paleiron N, André M, Caliandro R, Bretel JJ, Terrier P, Margery J, Le Chevalier T, Ruffié P. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. J Thorac Oncol. 2010 Jun;5(6):893-7. [PubMed: 20521356]

14.

Shin W, Lee HJ, Yang SJ, Paik ES, Choi HJ, Kim TJ, Choi CH, Lee JW, Bae DS, Kim BG. Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. Obstet Gynecol Sci. 2018 May;61(3):352-358. [PMC free article: PMC5956118] [PubMed: 29780777]

15.

Sannu A, Radha R, Mathews A, Padmakumari Mony R, Prahladan A, James FV. Ifosfamide-Induced Malignancy of Ureter and Bladder. Cureus. 2017 Aug 22;9(8):e1594. [PMC free article: PMC5650260] [PubMed: 29062626]

16.

Voelcker G. Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity. Anticancer Drugs. 2018 Jan;29(1):75-79. [PubMed: 29219879]

17.

Kerbusch T, de Kraker J, Keizer HJ, van Putten JW, Groen HJ, Jansen RL, Schellens JH, Beijnen JH. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet. 2001 Jan;40(1):41-62. [PubMed: 11236809]

18.

Han HY, Choi MS, Yoon S, Ko JW, Kim SK, Kim TW. Investigation of Ifosfamide Toxicity Induces Common Upstream Regulator in Liver and Kidney. Int J Mol Sci. 2021 Nov 11;22(22) [PMC free article: PMC8617928] [PubMed: 34830083]

19.

Kataria PS, Kendre PP, Patel AA. Ifosfamide-induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction. J Pharmacol Pharmacother. 2017 Jan-Mar;8(1):38-40. [PMC free article: PMC5370329] [PubMed: 28405136]

20.

Shimada K, Hasegawa S, Nakao S, Mukai R, Matsumoto K, Tanaka M, Uranishi H, Masuta M, Nishida S, Shimizu S, Hayashi Y, Suzuki A, Nakamura M. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases. Cancer Chemother Pharmacol. 2019 Nov;84(5):1097-1105. [PubMed: 31502115]

21.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Apr 15, 2018. Ifosfamide. [PMC free article: PMC547852] [PubMed: 31643882]

22.

ACOG Committee Opinion No. 747 Summary: Gynecologic Issues in Children and Adolescent Cancer Patients and Survivors. Obstet Gynecol. 2018 Aug;132(2):535-536. [PubMed: 30045207]

23.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Oct 19, 2020. Ifosfamide. [PubMed: 33104314]

24.

Klastersky J. Side effects of ifosfamide. Oncology. 2003;65 Suppl 2:7-10. [PubMed: 14586140]

25.

Dupuis LL, Boodhan S, Holdsworth M, Robinson PD, Hain R, Portwine C, O'Shaughnessy E, Sung L., Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2013 Jul;60(7):1073-82. [PubMed: 23512831]

26.

Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005 Oct 20;23(30):7685-96. [PubMed: 16234530]

27.

Luminais SN, Chen XT, Roman D, Ma B, Christ AB, Hu JS. Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature. J Med Case Rep. 2022 Jun 28;16(1):252. [PMC free article: PMC9238137] [PubMed: 35761364]

28.

Kerbusch T, Jansen RL, Mathôt RA, Huitema AD, Jansen M, van Rijswijk RE, Beijnen JH. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Clin Pharmacol Ther. 2001 Aug;70(2):132-41. [PubMed: 11503007]

29.

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol. 2017 Oct;83(10):2148-2162. [PMC free article: PMC5595939] [PubMed: 28470980]

30.

Matz EL, Hsieh MH. Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis. Urology. 2017 Feb;100:16-19. [PubMed: 27566144]

31.

Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol. 2006 Feb;33(1):50-67. [PubMed: 16473644]

32.

Banh C, Valsvik K, Arredondo A, Notbohm K, Elquza E, Babiker H, Kraft A, Boiles AR, Persky D, Ortega A, McBride A. Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile. Support Care Cancer. 2022 Mar;30(3):2755-2766. [PMC free article: PMC8617555] [PubMed: 34825982]

33.

Kerbusch T, Jeuken MJ, Derraz J, van Putten JW, Huitema AD, Beijnen JH. Determination of ifosfamide, 2- and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection. Ther Drug Monit. 2000 Oct;22(5):613-20. [PubMed: 11034269]

34.

Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995 Jan;21(1):33-64. [PubMed: 7859226]

35.

Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH., American Society of Clinical Oncology. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012 May 01;30(13):1553-61. [PubMed: 22473167]

36.

Nicolao P, Giometto B. Neurological toxicity of ifosfamide. Oncology. 2003;65 Suppl 2:11-6. [PubMed: 14586141]

37.

Turner AR, Duong CD, Good DJ. Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. Clin Oncol (R Coll Radiol). 2003 Oct;15(7):435-9. [PubMed: 14570094]

38.

Snyder M, Gangadhara S, Brohl AS, Ludlow S, Nanjappa S. Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue. Cancer Control. 2017 Oct-Dec;24(5):1073274817729070. [PMC free article: PMC5937239] [PubMed: 28975823]

39.

Morgan LR, Harrison EF, Hawke JE, Hunter HL, Costanzi JJ, Plotkin D, Tucker WG, Worrall PM. Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study. Semin Oncol. 1982 Dec;9(4 Suppl 1):66-70. [PubMed: 7163813]

40.

Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, Strasfeld L, Flowers CR. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018 Oct 20;36(30):3043-3054. [PubMed: 30179565]

41.

Loebstein R, Koren G. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics. 1998 Jun;101(6):E8. [PubMed: 9606250]

42.

Porta C, Bamias A, Danesh FR, Dębska-Ślizień A, Gallieni M, Gertz MA, Kielstein JT, Tesarova P, Wong G, Cheung M, Wheeler DC, Winkelmayer WC, Małyszko J., Conference Participants. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney Int. 2020 Nov;98(5):1108-1119. [PubMed: 33126977]

43.

Kandylis K, Vassilomanolakis M, Tsoussis S, Efremidis AP. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol. 1989;24(6):395-6. [PubMed: 2791194]

44.

A Carrasquillo M, A Vest T, S Bates J, Faso A, Auten J, Buchanan I, McCann M, Carey L, Amerine LB. A chemotherapy privileging process for advanced practice providers at an academic medical center. J Oncol Pharm Pract. 2020 Jan;26(1):116-123. [PubMed: 31096855]

Disclosure: Mounika Gangireddy declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Vinod Nookala declares no relevant financial relationships with ineligible companies.